Apex Biochemical Exports Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.46 M
as on 17-11-2024
- Revenue -91.10%
(FY 2023)
- Profit -328.54%
(FY 2023)
- Ebitda 92.79%
(FY 2023)
- Net Worth -19.56%
(FY 2023)
- Total Assets -55.14%
(FY 2023)
About Apex Biochemical Exports
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.46 M.
Syed Hussain and Aisha Hussain serve as directors at the Company.
- CIN/LLPIN
U51909WB2019PTC232443
- Company No.
232443
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Apex Biochemical Exports?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Syed Hussain  | Director | 13-Jun-2019 | Current |
| Aisha Hussain | Director | 13-Jun-2019 | Current |
Financial Performance of Apex Biochemical Exports.
Apex Biochemical Exports Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 91.1% decrease. The company also saw a substantial fall in profitability, with a 328.54% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apex Biochemical Exports?
In 2023, Apex Biochemical Exports had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Robust Fitness Private LimitedActive 8 years 6 monthsSyed Hussain and Aisha Hussain are mutual person
Womax Exports Private LimitedActive 15 years 9 monthsSyed Hussain and Aisha Hussain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 11 Nov 2021 | ₹1.46 M | Open |
How Many Employees Work at Apex Biochemical Exports?
Apex Biochemical Exports has a workforce of 8 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apex Biochemical Exports, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apex Biochemical Exports's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
